Document is current
Any future updates will be listed below
-
Authors
Sandforth, Arvid https://orcid.org/0009-0009-5374-1260
Arreola, Elsa Vazquez https://orcid.org/0000-0003-1960-1159
Hanson, Robert L.
Wewer Albrechtsen, Nicolai J. https://orcid.org/0000-0003-4230-5753
Holst, Jens Juul https://orcid.org/0000-0001-6853-3805
Ahrends, Robert https://orcid.org/0000-0003-0232-3375
Coman, Cristina
Gerst, Felicia
Lorza-Gil, Estela
Cheng, Yurong
Sandforth, Leontine
Katzenstein, Sarah
Ganslmeier, Marlene
Seissler, Jochen
Hauner, Hans
Perakakis, Nikolaos
Wagner, Robert
Machann, Jürgen https://orcid.org/0000-0002-4458-5886
Schick, Fritz https://orcid.org/0000-0002-4231-3406
Peter, Andreas https://orcid.org/0000-0001-5732-2287
Lehmann, Rainer https://orcid.org/0000-0003-1218-6810
Weigert, Cora
Maurer, Jennifer
Preissl, Hubert https://orcid.org/0000-0002-8859-4661
Heni, Martin https://orcid.org/0000-0002-8462-3832
Szendrödi, Julia
Kopf, Stefan
Solimena, Michele https://orcid.org/0000-0002-3653-8107
Schwarz, Peter
Blüher, Matthias https://orcid.org/0000-0003-0208-2065
Häring, Hans-Ulrich
Hrabé de Angelis, Martin https://orcid.org/0000-0002-7898-2353
Schürmann, Annette https://orcid.org/0000-0002-4113-4377
Kabisch, Stefan
Mai, Knut
Pfeiffer, Andreas F. H.
Bornstein, Stefan https://orcid.org/0000-0002-5211-2536
Stumvoll, Michael
Roden, Michael https://orcid.org/0000-0001-8200-6382
Stefan, Norbert https://orcid.org/0000-0002-2186-9595
Fritsche, Andreas
Birkenfeld, Andreas L. https://orcid.org/0000-0003-1407-9023
Jumpertz von Schwartzenberg, Reiner https://orcid.org/0000-0002-5544-099X
-
Funding
Funding for this research was provided by:
Helmholtz Association (VH-NG-1619)
Deutsche Forschungsgemeinschaft (EXC 2124 - 03.007)
- License Information
-
More Information
Article History
Received: 14 February 2025
Accepted: 6 August 2025
First Online: 29 September 2025
Competing interests
: S.K. receives grants from the German Diabetes Association, Wilhelm Doerenkamp Foundation and California Walnut Commission, and lecture fees from Sanofi, Boehringer Ingelheim, Berlin Chemie, Lilly Deutschland and Juzo Akademie. R.W. receives lecture fees from Eli Lilly, Novo Nordisk and Sanofi, and participates in a Data Safety Monitoring Board and Advisory Board for Eli Lilly. N.P. receives lecture fees from Novo Nordisk and Gesellschaft für Wissenschaftstransfer Dresden, advisory board fees from Bayer Vital and holds patent WO2021/092265A1 for diagnosis and treatment of nonalcoholic fatty liver disease and liver fibrosis. J.J.H. is consulting with Novo Nordisk. N.J.W.A. has received research support and speaker fees from Mercodia, Novo Nordisk, Merck/MSD and Boehringer Ingelheim. All other authors declare no competing interests.
